Early evidence suggests safety, efficacy, while awaiting data on durability in broader pop ...

Low-dose aspirin may limit cancer metastasis by inhibiting platelet activation and enhancing T-cell immunity, supporting biomarker guided use while balancing bleeding risk overall.

CD8 + cytotoxic T lymphocytes (CTLs) serve as central effectors in cancer immunotherapy by directly eliminating tumor cells. However, current clinical therapies face significant limitations. These ...

Janux Therapeutics, Inc. (Nasdaq: JANX) ("Janux"), a clinical-stage biopharmaceutical company developing a broad pipeline of ...

A team from the Max Planck Research Group for Systems Immunology at the University of Würzburg has identified a previously unknown phase of the immune response. The results, published in Science, ...

Janux Therapeutics and Bristol Myers Squibb (BMS) are developing a tumor-activated therapeutic in an exclusive licensing agreement.